Amrita Pathak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amrita Pathak has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Bruce D. Carter
Department of Biochemistry and Vanderbilt Brain Institute, Vanderbilt University School of Medicine Basic Sciences, Nashville, TN
19 shared publications Andrew L. Kung
13 shared publicationsErin Moroze
13 shared publicationsJohn A. DeSisto
13 shared publicationsNatalie J. Bales
13 shared publicationsNatalie Philips
13 shared publications
Latest Publications
- Open Access
Palmitoylation of the p75 neurotrophin receptor is required for retrograde regressive signaling
Target-derived neurotrophins regulate neuronal survival and pruning via retrograde signaling. Unlike Trk receptors, which are transported as transmembrane proteins, the p75 neurotrophin receptor (p75NTR) undergoes regulated intramembrane proteolysis to release a soluble intracellular domain (ICD) that must somehow associate with axonal endosomes for retrograde transport. Here, we identify palmitoylation of a conserved juxta membrane cysteine (C281) as a critical requirement for this process. In sympathetic neurons, we demonstrate that p75NTR palmitoylation is dispensable for surface trafficking and proteolytic cleavage but is strictly required for ligand-induced internalization and the biogenesis of p75ICD-positive signaling endosomes. Consequently, blocking palmitoylation, either pharmacologically or via a palmitoylation-deficient C281A mutation, prevents the accumulation of p75ICD in axonal endosomes and blocks axon-initiated apoptosis. In vivo , C281A knock-in mice exhibit reduced developmental apoptosis of sympathetic neurons, similar to p75NTR deletion. These findings define palmitoylation as an essential checkpoint that couples p75NTR cleavage to endosomal segregation, thereby enabling the long-distance transmission of regressive signals. Synopsis: The intracellular domain (ICD) of neurotrophin receptor p75NTR is a long-distance death signal generated by its local cleavage in axons. Palmitoylation at conserved juxtamembrane Cysteine residue is necessary for ligand induced receptor internalization and provides a tether for attaching the cleaved p75ICD to regressive signaling endosomes leading to retrograde neuron death.
Open AccessPalmitoylation of the p75 neurotrophin receptor is required for retrograde regressive signaling
Target-derived neurotrophins regulate neuronal survival and pruning via retrograde signaling. Unlike Trk receptors, which are transported as transmembrane proteins, the p75 neurotrophin receptor (p75NTR) undergoes regulated intramembrane proteolysis to release a soluble intracellular domain (ICD) that must somehow associate with axonal endosomes for retrograde transport. Here, we identify palmitoylation of a conserved juxta membrane cysteine (C281) as a critical requirement for this process. In sympathetic neurons, we demonstrate that p75NTR palmitoylation is dispensable for surface trafficking and proteolytic cleavage but is strictly required for ligand-induced internalization and the biogenesis of p75ICD-positive signaling endosomes. Consequently, blocking palmitoylation, either pharmacologically or via a palmitoylation-deficient C281A mutation, prevents the accumulation of p75ICD in axonal endosomes and blocks axon-initiated apoptosis. In vivo , C281A knock-in mice exhibit reduced developmental apoptosis of sympathetic neurons, similar to p75NTR deletion. These findings define palmitoylation as an essential checkpoint that couples p75NTR cleavage to endosomal segregation, thereby enabling the long-distance transmission of regressive signals. Synopsis: The intracellular domain (ICD) of neurotrophin receptor p75NTR is a long-distance death signal generated by its local cleavage in axons. Palmitoylation at conserved juxtamembrane Cysteine residue is necessary for ligand induced receptor internalization and provides a tether for attaching the cleaved p75ICD to regressive signaling endosomes leading to retrograde neuron death.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table 1 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Cell line characteristics and selinexor in vitro IC50 levels
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table 1 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Cell line characteristics and selinexor in vitro IC50 levels
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table 2 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
NCI approved anti-cancer agents in combination drug screen with selinexor
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table 2 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
NCI approved anti-cancer agents in combination drug screen with selinexor
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table 1 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Cell line characteristics and selinexor in vitro IC50 levels
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table 1 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Cell line characteristics and selinexor in vitro IC50 levels
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table 3 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Summary of p-NF-KB and NF-KB values and ratios from Figure 1f, h and i
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table 3 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
Summary of p-NF-KB and NF-KB values and ratios from Figure 1f, h and i
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supp. Table 2 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
NCI approved anti-cancer agents in combination drug screen with selinexor
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupp. Table 2 from Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
NCI approved anti-cancer agents in combination drug screen with selinexor